KR102481945B1 - Cosmetic composition for scalp and hair containing natural complex extract as an active ingredient - Google Patents
Cosmetic composition for scalp and hair containing natural complex extract as an active ingredient Download PDFInfo
- Publication number
- KR102481945B1 KR102481945B1 KR1020220057188A KR20220057188A KR102481945B1 KR 102481945 B1 KR102481945 B1 KR 102481945B1 KR 1020220057188 A KR1020220057188 A KR 1020220057188A KR 20220057188 A KR20220057188 A KR 20220057188A KR 102481945 B1 KR102481945 B1 KR 102481945B1
- Authority
- KR
- South Korea
- Prior art keywords
- fruit
- hair
- extract
- cosmetic composition
- root
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 92
- 210000004209 hair Anatomy 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 239000002537 cosmetic Substances 0.000 title claims abstract description 17
- 239000004480 active ingredient Substances 0.000 title claims abstract description 15
- 210000004761 scalp Anatomy 0.000 title claims abstract description 13
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 29
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 28
- 239000010018 saw palmetto extract Substances 0.000 claims abstract description 22
- 230000003779 hair growth Effects 0.000 claims abstract description 21
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 17
- 244000172730 Rubus fruticosus Species 0.000 claims abstract description 16
- 235000017848 Rubus fruticosus Nutrition 0.000 claims abstract description 16
- 230000001737 promoting effect Effects 0.000 claims abstract description 13
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 12
- 230000003658 preventing hair loss Effects 0.000 claims abstract description 8
- 238000004140 cleaning Methods 0.000 claims abstract description 4
- 231100001083 no cytotoxicity Toxicity 0.000 claims abstract description 3
- 240000000908 Phyllanthus acidus Species 0.000 claims abstract 5
- 239000002994 raw material Substances 0.000 claims description 19
- 230000002500 effect on skin Effects 0.000 claims description 15
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 14
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 claims description 13
- 230000002292 Radical scavenging effect Effects 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 230000002000 scavenging effect Effects 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 38
- 230000008099 melanin synthesis Effects 0.000 abstract description 15
- 102000003425 Tyrosinase Human genes 0.000 abstract description 14
- 108060008724 Tyrosinase Proteins 0.000 abstract description 14
- 239000003102 growth factor Substances 0.000 abstract description 13
- 102000004169 proteins and genes Human genes 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 230000010261 cell growth Effects 0.000 abstract description 5
- 239000002131 composite material Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- 244000119298 Emblica officinalis Species 0.000 description 23
- 238000002835 absorbance Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000003020 moisturizing effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 9
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 150000002989 phenols Chemical class 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 229930003935 flavonoid Natural products 0.000 description 7
- 150000002215 flavonoids Chemical class 0.000 description 7
- 235000017173 flavonoids Nutrition 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 201000004384 Alopecia Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229920001864 tannin Polymers 0.000 description 6
- 235000018553 tannin Nutrition 0.000 description 6
- 239000001648 tannin Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 5
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 5
- 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229940018044 saw palmetto fruit extract Drugs 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 239000000118 hair dye Substances 0.000 description 4
- 230000003676 hair loss Effects 0.000 description 4
- 208000024963 hair loss Diseases 0.000 description 4
- -1 malt extract Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000404305 Erica arborea Species 0.000 description 3
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 3
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 241000109365 Rosa arkansana Species 0.000 description 3
- 235000005066 Rosa arkansana Nutrition 0.000 description 3
- 240000006661 Serenoa repens Species 0.000 description 3
- 235000005318 Serenoa repens Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 244000050053 Rosa multiflora Species 0.000 description 2
- 235000000656 Rosa multiflora Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940117382 propecia Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000010421 standard material Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- GSFDOOHGKOHDEL-UHFFFAOYSA-N Dalpanitin Natural products COc1cc(ccc1O)C2=COc3c(C4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3C2=O GSFDOOHGKOHDEL-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- ZCSDEGFPWXFQLB-UHFFFAOYSA-N Kaempferol 3-O-beta-D-glucorhamnoside Natural products OC1C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(C)OC1OC(C(C1=C(O)C=C(O)C=C1O1)=O)=C1C1=CC=C(O)C=C1 ZCSDEGFPWXFQLB-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- ZCSDEGFPWXFQLB-SFIZVBBHSA-N Multifloein B Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@H](OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O[C@H]1C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ZCSDEGFPWXFQLB-SFIZVBBHSA-N 0.000 description 1
- KXOPSQZLBRPJGX-RHTLDPNOSA-N Multiflorin A Chemical compound O([C@H]1OC([C@@H](C(O)[C@@H]1O)O[C@H]1C(C(O)[C@H](O)C(COC(C)=O)O1)O)C)C(C(C1=C(O)C=C(O)C=C1O1)=O)=C1C1=CC=C(O)C=C1 KXOPSQZLBRPJGX-RHTLDPNOSA-N 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241000233910 Serenoa Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- SOSLMHZOJATCCP-PADPQNGGSA-N afzelin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2ccc(O)cc2)Oc2c(c(O)cc(O)c2)C1=O SOSLMHZOJATCCP-PADPQNGGSA-N 0.000 description 1
- SOSLMHZOJATCCP-AEIZVZFYSA-N afzelin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O SOSLMHZOJATCCP-AEIZVZFYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000002012 ayurvedic medicine Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- ALRFYJWUVHBXLV-UHFFFAOYSA-N guaijaverin Natural products OC1COC(COC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O ALRFYJWUVHBXLV-UHFFFAOYSA-N 0.000 description 1
- 230000003700 hair damage Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- BCUMVYNRIHNHEC-UHFFFAOYSA-N multiflorin A Natural products CC1OC(OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)cc4)C(OC(=O)C)C(O)C1OC5OC(CO)C(O)C(O)C5O BCUMVYNRIHNHEC-UHFFFAOYSA-N 0.000 description 1
- ZCSDEGFPWXFQLB-WRHRXROUSA-N multiflorin B Chemical compound O([C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)C(C(C1=C(O)C=C(O)C=C1O1)=O)=C1C1=CC=C(O)C=C1 ZCSDEGFPWXFQLB-WRHRXROUSA-N 0.000 description 1
- NJGXUUJRKHPLLB-UHFFFAOYSA-N multiflorin B Natural products CCC1OC(OC2C(C)OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)cc5)C(O)C2O)C(O)C(O)C1O NJGXUUJRKHPLLB-UHFFFAOYSA-N 0.000 description 1
- CAENGMLSMONNBU-QLYOBGCHSA-N multinoside A Chemical compound O([C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)C(C(C1=C(O)C=C(O)C=C1O1)=O)=C1C1=CC=C(O)C(O)=C1 CAENGMLSMONNBU-QLYOBGCHSA-N 0.000 description 1
- MXTLTYZWSDKPSY-UHFFFAOYSA-N multinoside A Natural products CCC1OC(OC2C(C)OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O MXTLTYZWSDKPSY-UHFFFAOYSA-N 0.000 description 1
- AATRYBSLZLJIJX-UHFFFAOYSA-N multinoside A acetate Natural products OC1C(O)C(OC2C(C(O)C(O)C(COC(C)=O)O2)O)C(C)OC1OC(C(C1=C(O)C=C(O)C=C1O1)=O)=C1C1=CC=C(O)C(O)=C1 AATRYBSLZLJIJX-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- SVHDRHWULLNMQC-UHFFFAOYSA-N scoparone Natural products C1=CC(=O)OC2=C1C=C(C(=O)C)C(C(C)=O)=C2 SVHDRHWULLNMQC-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229960000819 sodium nitrite Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 천연 복합추출물을 유효성분으로 함유하는 두피 및 모발용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for scalp and hair containing a natural complex extract as an active ingredient.
모발을 잘 자라게 하기 위해서는 모유두(papilla)의 역할이 중요하다. 그러나 모유두는 일생 동안 활동하고 모발을 계속 만들지는 않는다. 어느 정도 활동을 계속하면 일시 활동을 멈춘다. 모발은 생장기(anagen), 퇴행기(catagen) 및 휴지기(telogen)의 성장주기를 반복하는데, 정상적인 두피에서 90 내지 95 %는 생장기에 있고, 1 %미만은 퇴화기에 있으며, 5 내지 10 %는 휴지기에 있어 매일 60 내지 80 개 이상의 모발이 휴지기에 접어들고 같은 수의 모낭은 다시 생장기로 들어간다. 따라서, 매일 60 내지 80 개 이상의 모발이 탈락되고 새로 생성되는데, 모발이 비정상적으로 이보다 많게 탈락되거나 재생되지 않는 증상을 탈모증(alopecia)이라 한다.In order for hair to grow well, the role of the papilla is important. However, dermal papillae are active throughout life and do not produce hair continuously. If activity continues to a certain extent, activity temporarily ceases. Hair repeats the growth cycle of anagen, catagen, and telogen. In normal scalp, 90 to 95% is in the anagen phase, less than 1% is in the catagen phase, and 5 to 10% is in the telogen phase. 60 to 80 or more hairs enter the telogen phase every day, and the same number of hair follicles enter the anagen phase again. Therefore, 60 to 80 or more hairs fall out and are newly generated every day, and a symptom in which more hairs are abnormally dropped or not regenerated is called alopecia.
상기 탈모증의 치료 방법으로는 경피 도포제로서 미녹시딜(Minoxidil)과 경구 복용제로서 프로페시아(Propecia)가 FDA의 승인을 받은 유일한 의약품으로 많이 사용되고 있다.As a treatment method for the alopecia, Minoxidil as a transdermal application agent and Propecia as an oral agent are widely used as the only pharmaceuticals approved by the FDA.
상기 미녹시딜의 경우 모발의 성장기(anagen phase)를 지연시킴으로써 모발성장을 촉진시키며, 혈관확장으로 인한 영양공급 증가 및 칼륨 통로 열림(potassium channel opening)효과 등에 의해 모발성장을 유도하는 것으로 보고되었으나, 아직까지도 그 기전은 명확하게 규명되어 있지 않다. 미녹시딜은 효과 유지를 위하여 지속적인 사용이 요구되어지며, 임상사례로부터 체중 증가, 부종, 협심증, 피부염 및 소양증 등이 보고되어졌으며 또한, 홍반, 가려움증, 표피박리 및 건성화를 동반한 피부염 및 과잉 도포 시 급격한 혈압강하를 초래하는 등 부작용을 초래할 수 있다.In the case of the minoxidil, it has been reported that it promotes hair growth by delaying the anagen phase of hair, and induces hair growth by increasing nutrient supply and potassium channel opening effect due to vasodilation, but still The mechanism has not been clearly elucidated. Continuous use of minoxidil is required to maintain the effect, and weight gain, edema, angina, dermatitis and pruritus have been reported from clinical cases, and dermatitis accompanied by erythema, itching, epidermal peeling and dryness, and rapid application in case of excessive application. It can cause side effects such as lowering blood pressure.
상기 프로페시아는 5α-환원효소(5α-reductase)의 활성을 억제시킴으로써 탈모의 진행 지연 및 발모효과를 지니지만 효과유지를 위한 장기복용은 남성 성기능 장애 및 여성 기형아 출산과 같은 심각한 부작용을 초래할 수 있다.Propecia has the effect of delaying the progress of hair loss and hair growth by inhibiting the activity of 5α-reductase, but long-term administration for maintaining the effect may cause serious side effects such as male sexual dysfunction and birth defects in females.
이러한 부작용은 탈모에 대한 적극적인 치료에 상당한 제한성을 가지고 있다고 볼 수 있다. 따라서 최근에는 이러한 단점을 보완하고 지속적 사용에도 안전한 다양한 천연추출물 및 한약소재를 사용하는 대체의학이 주목받고 있다.These side effects can be seen as having significant limitations in active treatment for hair loss. Therefore, in recent years, alternative medicine that compensates for these disadvantages and uses various natural extracts and herbal medicine materials that are safe for continuous use is attracting attention.
한편, 백모 개선을 위해서는 주로 염모제를 사용하는 것이 일반적인데, 천연식물을 이용한 염모제는 색상이 제한적이며 색 지속력이 짧다는 단점이 있다. 화학적 염모제는 모발에 다양한 색상을 염색시키고 지속력도 우수한 장점이 있으나 두피자극, 모발손상 등의 부작용을 일으키기도 한다. 또한 기존의 염모제는 모발이 성장할수록 기존의 백모가 다시 드러나게 되어 반복된 염색을 요구한다는 점에서 문제점을 가지고 있다. 따라서 단순히 모발을 검게 염색하는 것에서 더 나아가 두피 멜라닌 세포를 자극하여 멜라닌 생성을 증가시킴으로써 모발을 지속적으로 검게할 수 있는 안전하고 두피에 자극이 적은 천연소재의 개발이 필요한 실정이다.On the other hand, in order to improve gray hair, it is common to use hair dyes mainly, but hair dyes using natural plants have a disadvantage in that the color is limited and the color durability is short. Chemical hair dyes dye hair in various colors and have excellent durability, but they also cause side effects such as scalp irritation and hair damage. In addition, existing hair dyes have a problem in that as the hair grows, the existing white hair is revealed again, requiring repeated dyeing. Therefore, it is necessary to develop a natural material that is safe and less irritating to the scalp, which can go beyond simply dyeing hair black and increase melanin production by stimulating scalp melanocytes to continuously blacken hair.
본 발명은 천연 복합추출물을 유효성분으로 함유하는 탈모 예방용, 발모 촉진용, 모발 흑화용 및 항산화용 화장료 조성물을 이용함으로써, 기존 화학적 조성물의 부작용을 방지하여 안전하고 두피에 자극이 적은 천연 복합추출물을 제공하고자 한다.The present invention is a natural complex extract that is safe and less irritating to the scalp by preventing the side effects of existing chemical compositions by using a cosmetic composition for preventing hair loss, promoting hair growth, blackening hair, and antioxidation containing a natural complex extract as an active ingredient. want to provide
본 발명은 인디안구스베리 열매, 찔레나무 뿌리 및 쏘팔메토 열매의 추출물을 유효성분으로 함유하는 탈모 예방용, 발모 촉진용, 모발 흑화용 또는 두피 청정용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for preventing hair loss, promoting hair growth, blackening hair or cleaning the scalp, containing extracts of Indian gooseberry fruit, bramble root, and saw palmetto fruit as active ingredients.
또한, 본 발명은 인디안구스베리 열매, 찔레나무 뿌리 및 쏘팔메토 열매의 추출물을 유효성분으로 함유하는 항산화용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for antioxidant containing extracts of Indian gooseberry fruit, bramble root and saw palmetto fruit as active ingredients.
추가적으로, 본 발명은 1) 건조 분말 원료를 건조하고 분쇄 및 동결하는 단계; 2) 상기 동결한 건조 분말 원료를 추출하는 단계; 3) 여과하여 잔유물을 분리하고 여과물을 수득하는 단계; 4) 상기 여과물을 회전 감압 농축하는 단계; 및 5) 상기 감압 농축처리된 추출물을 동결 건조하여 천연 혼합 원료를 얻는 단계를 포함하는 인디안구스베리 열매, 찔레나무 뿌리 및 쏘팔메토 열매의 추출물을 유효성분으로 함유한 조성물의 제조방법을 제공한다.Additionally, the present invention includes the steps of 1) drying, pulverizing and freezing the dry powder raw material; 2) extracting the frozen dry powder raw material; 3) filtering to separate the residue and obtain a filtrate; 4) concentrating the filtrate under rotary reduced pressure; and 5) obtaining a natural mixed raw material by freeze-drying the concentrated extract under reduced pressure.
본 발명에 따르면, 인디안구스베리 열매, 찔레나무 뿌리 및 쏘팔메토 열매의 추출물이 (1~5):(1~3):1의 중량비로 혼합되어 있는 복합추출물을 유효성분으로 함유하는 조성물은 각각의 추출물 대비 항산화능이 우수하고 티로시나아제(tyrosinase)의 활성 및 멜라닌 생성을 증가시키며, 인간 모유두세포(HFDPC)에서 세포 독성이 관찰되지 않아 세포 생육도가 우수하고 모발성장인자 단백질의 발현 효과를 나타내는 것이 확인됨에 따라, 상기 복합추출물을 탈모 예방용, 발모 촉진용, 모발 흑화용, 두피 청정용 및 항산화용 화장료 조성물로 제공하고자 한다.According to the present invention, a composition containing, as an active ingredient, a complex extract in which extracts of Indian gooseberry fruit, bramble root, and saw palmetto fruit are mixed in a weight ratio of (1 to 5):(1 to 3):1 It has excellent antioxidant performance compared to the extract of tyrosinase, increases the activity of tyrosinase and melanin production, and has no cytotoxicity in human dermal papilla cells (HFDPC), so it has excellent cell growth and shows the expression effect of hair growth factor protein. As it is confirmed, it is intended to provide the composite extract as a cosmetic composition for preventing hair loss, promoting hair growth, blackening hair, cleaning the scalp and antioxidant.
도 1은 본 발명의 복합추출물 및 비교 대조군의 보습력 테스트 데이터를 나타낸 그래프이다.
도 2는 본 발명의 복합추출물 및 각각의 추출물의 DPPH 라디칼 소거능을 나타낸 그래프이다.
도 3은 본 발명의 복합추출물 및 각각의 추출물의 아질산염 소거능을 나타낸 그래프이다.
도 4는 5: 1: 1 천연 복합추출물의 세포 티로시나아제 분석(cellular tyrosinase assay)를 수행한 결과를 나타낸 그래프이다.
도 5는 5: 1: 1 천연 복합 추출물의 멜라닌 생성 증가 효능을 계산한 결과를 나타낸 그래프이다.
도 6은 인간 모유두세포에 대하여 5: 1: 1 천연 복합추출물을 농도별로 처리하고 MTT assay로 세포 독성을 확인하여 세포 생육도를 나타낸 그래프이다.
도 7은 인간 모유두세포에 5: 1: 1 천연 복합추출물이 모발성장인자들의 발현 정도에 미치는 영향을 웨스턴블랏(western blot)을 통해 측정한 그래프이다.1 is a graph showing the moisturizing test data of the composite extract and comparative control group of the present invention.
Figure 2 is a graph showing the DPPH radical scavenging ability of the composite extract and each extract of the present invention.
Figure 3 is a graph showing the nitrite scavenging ability of the composite extract and each extract of the present invention.
Figure 4 is a graph showing the results of performing a cellular tyrosinase assay of a 5: 1: 1 natural composite extract.
5 is a graph showing the results of calculating the melanin production increasing efficacy of a 5: 1: 1 natural complex extract.
Figure 6 is a graph showing the degree of cell viability by treating human dermal papilla cells with a 5: 1: 1 natural composite extract by concentration and confirming cytotoxicity by MTT assay.
Figure 7 is a graph measuring the effect of a 5: 1: 1 natural composite extract on the expression level of hair growth factors in human dermal papilla cells through western blot.
이하, 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명자는 인디안구스베리 열매, 찔레뿌리, 쏘팔메토 열매로부터 유효물질을 추출하여 항산화능 실험, 인간모유두세포의 세포 증식효과 및 웨스턴블랏으로 모낭에서 모발의 성장에 역할을 하는 성장인자의 발현촉진 효과를 연구하여 약물 요법을 대체할 수 있는 천연성분을 이용한 탈모 예방용, 발모 촉진용 및 모발 흑화용 천연 복합 소재 개발 가능성을 확인함에 따라, 본 발명을 완성하였다.The present inventors extracted active substances from Indian gooseberry fruit, wild rose root, and saw palmetto fruit to test antioxidant capacity, promote the expression of growth factors that play a role in hair growth in hair follicles by testing the cell proliferation effect of human hair papilla cells, and Western blot. was studied to confirm the possibility of developing a natural composite material for preventing hair loss, promoting hair growth, and blackening hair using natural ingredients that can replace drug therapy, thereby completing the present invention.
본 발명은 인디안구스베리 열매, 찔레나무 뿌리 및 쏘팔메토 열매의 추출물을 유효성분으로 함유하는 탈모 예방용, 두피 청정용 또는 모발흑화용 화장료 조성물을 제공할 수 있다.The present invention can provide a cosmetic composition for preventing hair loss, purifying the scalp, or blackening hair, containing extracts of Indian gooseberry fruit, bramble root, and saw palmetto fruit as active ingredients.
상기 인디안구스베리는 암라(Amla)로도 알려져 있으며 인도, 중동, 일부 동남아시아에서 자라는 낙엽 교목의 과일로 인도의 아유르베다(Ayurvedic) 의학에서 고대부터 건강에 중요한 상징으로 사용되어 왔고, 각종 질병과 노화를 방지하고 미용과 건강에 효과가 높은 물질로 소개되었으며, 비타민 C와 phenolic compound, tannins, rutin, curcuminoids, emblicol 등 다양한 항산화 물질들이 함유되어 있어 항산화 활성이나 지질 과산화(lipid peroxidation) 억제 효과 등이 있다고 알려진 것일 수 있다.The Indian gooseberry, also known as Amla, is a fruit of a deciduous tree that grows in India, the Middle East and some Southeast Asian countries, and has been used as an important symbol for health since ancient times in Ayurvedic medicine in India, and has been used to prevent various diseases and aging. It has been introduced as a substance that is highly effective for beauty and health, and contains various antioxidant substances such as vitamin C, phenolic compound, tannins, rutin, curcuminoids, and emlicol, which are known to have antioxidant activity or lipid peroxidation inhibitory effects. can
상기 찔레나무(Rosa multiflora Thunberg) 뿌리는 장미과(Rosaceae)에 속하며 한의학에서는 석산호로 불리고 있으며, 열매는 영실 또는 색미자라 하여 약으로 쓰이는 것일 수 있다. 뿌리는 청열, 이습, 거풍 또는 활혈에 효능이 있어 당뇨병, 이질, 관절염, 토혈, 유뇨증, 월경불순, 타박상의 치료목적으로 민간에서 사용되는 것일 수 있다. 찔레나무의 성분으로는 주로 찔레의 과실인 영실로부터 multiflorin A, multiflorin B, Kaempferol 3-O-α-L-rhamnoside, multinoside A, multinoside A acetate, quercitrin, isoquercitrin, quercetin 3-O-xyloside, hyperin 등의 flavonoid류와 scoparone, salicyclic acid, sterol 등일 수 있다.The root of the briar tree (Rosa multiflora Thunberg) belongs to the Rosaceae family and is called stone coral in oriental medicine, and the fruit may be used as a medicine called Youngsil or Saekmija. The root may be used in the private sector for the treatment of diabetes, dysentery, arthritis, hematemesis, enuresis, menstrual irregularity, and bruises because it is effective in clearing heat, dampness, wind, or blood. Ingredients of brier tree include multiflorin A, multiflorin B, Kaempferol 3-O-α-L-rhamnoside, multinoside A, multinoside A acetate, quercitrin, isoquercitrin, quercetin 3-O-xyloside, hyperin, etc. of flavonoids, scoparone, salicyclic acid, and sterol.
또한, 상기 찔레나무는 예로부터 민간에서는 아주 귀한 약재로 가지와 줄기의 삶은 물로 머리를 감으면 탈모방지에 도움이 되고 비듬을 없애주는데 사용되었고, 항염증 활성을 나타내는 sterols 및 triterpenoids 성분이 알려져 있으며, 피부질환 개선 및 상처치유와 관련된 항염증 또는 항산화 효능 등의 효과가 있을 수 있다.In addition, the bramble tree has been used as a very precious medicinal material in the private sector since ancient times, and washing the head with boiled water of branches and stems helps to prevent hair loss and eliminates dandruff, and sterols and triterpenoids components exhibiting anti-inflammatory activity are known, It may have effects such as anti-inflammatory or antioxidant effects related to skin disease improvement and wound healing.
상기 쏘팔메토는 아메리카 대륙 카리브해에서 자생하는 식물로 아메리카 원주민들은 수세기 동안 음식과 치료약으로 쏘팔메토를 사용해왔으며, 이것을 섭취하거나 국소형태로 바를 경우 탈모를 줄이고 모발성장을 촉진할 수 있다는 연구결과가 있다. 쏘팔메토는 남성호르몬인 테스토스테론이 디하이드로 테스토스테론(dihydrotestosterone; DHT)로 전환되는 것을 억제할 수 있다.Saw palmetto is a plant native to the Caribbean in the Americas. Native Americans have been using saw palmetto as a food and medicine for centuries, and studies have shown that it can reduce hair loss and promote hair growth when ingested or applied topically. there is. Saw palmetto can inhibit the conversion of the male hormone testosterone to dihydrotestosterone (DHT).
상기 조성물은 인디안구스베리 열매, 찔레나무 뿌리 및 쏘팔메토 열매의 추출물을 (1~5):(1~3):1의 중량비로 포함한다. 바람직하게는 인디안구스베리 열매, 찔레나무 뿌리 및 쏘팔메토 열매의 추출물의 중량비가 5: 1: 1의 비율을 갖는 복합추출물이다. 상기 복합추출물은 단일성분인 인디안구스베리 열매, 찔레나무 뿌리 또는 쏘팔메토 열매로 이루어진 물질의 효력보다 현저히 높은 보습효과, 항산화 효과(폴리페놀 함량, 플라보노이드 함량, DPPH 라디칼 소거능, 아질산염 소거능), 모발 흑화 효과(Tyrosinase 활성 증가, 멜라닌 생성 촉진), 모발 성장인자 단백질 발현(western blot)를 나타낸다.The composition comprises extracts of Indian gooseberry fruit, bramble root and saw palmetto fruit in a weight ratio of (1-5):(1-3):1. Preferably, the weight ratio of extracts of Indian gooseberry fruit, bramble root and saw palmetto fruit is a composite extract having a ratio of 5: 1: 1. The composite extract has a significantly higher moisturizing effect, antioxidant effect (polyphenol content, flavonoid content, DPPH radical scavenging activity, nitrite scavenging activity), hair blackening than the effect of substances consisting of single-ingredient Indian gooseberry fruit, bramble root or saw palmetto fruit. It shows the effect (increased tyrosinase activity, promotion of melanin production) and hair growth factor protein expression (western blot).
본 발명은 인디안구스베리 열매, 찔레나무 뿌리 및 쏘팔메토 열매의 추출물을 유효성분으로 함유하는 항산화용 화장료 조성물을 제공할 수 있다.The present invention can provide a cosmetic composition for antioxidant containing extracts of Indian gooseberry fruit, bramble root and saw palmetto fruit as active ingredients.
또한, 본 발명은 1) 건조 분말 원료를 건조하고 분쇄 및 동결하는 단계(제1단계) 2) 상기 동결한 건조 분말 원료를 추출하는 단계(제2단계); 3) 여과하여 잔유물을 분리하고 여과물을 수득하는 단계(제3단계); 4) 상기 여과물을 회전 감압 농축하는 단계(제4단계); 및 5) 상기 농축처리된 추출물을 동결 건조하여 천연 혼합 연료를 얻는 단계(제5단계)를 포함하는 인디안구스베리 열매, 찔레나무 뿌리 및 쏘팔메토 열매의 추출물을 유효성분으로 함유한 조성물의 제조방법을 제공할 수 있다.In addition, the present invention comprises: 1) drying, pulverizing and freezing the dry powder raw material (first step) 2) extracting the frozen dry powder raw material (second step); 3) filtering to separate the residue and obtain a filtrate (third step); 4) concentrating the filtrate under reduced pressure by rotation (fourth step); And 5) Freeze-drying the concentrated extract to obtain a natural mixed fuel (step 5) A method for producing a composition containing extracts of Indian gooseberry fruit, bramble root and saw palmetto fruit as active ingredients can provide.
상기 건조된 분말 원료의 분쇄는 별도로 10 내지 40 mesh로 2차 분쇄할 것일 수 있다.The pulverization of the dried powder raw material may be secondary pulverization to 10 to 40 mesh separately.
상기 제1단계에서 동결은 사용의 용이와 원료수급 추출방법의 일원화를 위한 것으로 건조 분말 원료의 수분함량은 1 내지 13 %인 것일 수 있다.Freezing in the first step is for ease of use and unification of raw material supply and extraction methods, and the moisture content of the dry powder raw material may be 1 to 13%.
상기 제2단계인 원료를 추출하는 단계는 베이스 원료의 주요 성분의 손실 및 파괴를 최소화하기 위해 많은 문헌적 보고에 의해 식물성 원료의 성분 변형과 파괴를 최소화하는 추출방법 중 진공저온감압 추출법을 선택하여 3회 이상의 반복 추출을 통해 추출 수율의 평균값을 출하한 것일 수 있다.In order to minimize the loss and destruction of the main components of the base raw material, the second step of extracting the raw material is to select the vacuum low-temperature decompression extraction method among the extraction methods that minimize the transformation and destruction of the components of the vegetable raw material according to many literature reports. It may be that the average value of the extraction yield was shipped through three or more repeated extractions.
상기 진공저온감압 추출법은 유기 용매와 같은 별도의 여과 단계를 거치지 않고 정제수를 이용하여 추출하는 방법으로 진공상태로 압력을 조절하고, 대류현상을 이용하여 끓는점을 낮춰 55 내지 65 ℃의 낮은 온도에서 천연물의 성분 변형 및 파괴 없이 추출이 용이한 안정적인 추출방법일 수 있다.The vacuum low-temperature pressure extraction method is a method of extracting using purified water without going through a separate filtration step such as an organic solvent, adjusting the pressure in a vacuum state and lowering the boiling point using a convection phenomenon to lower the natural product at a low temperature of 55 to 65 ° C. It can be a stable extraction method that is easy to extract without transforming or destroying the components of
상기 여과는 여과지를 이용하여 여과물로부터 불순물 등을 거르는 1차 여과 과정 및 1차 여과된 여과물을 분말 활성탄을 활용하여 여과층을 형성한 후 통과시켜 여과물 내의 오염물질을 흡착하고 용매 및 식물 내의 엽록소 성분을 분리시키는 2차 여과과정을 포함하는 것일 수 있다.The filtration is a first filtration process of filtering out impurities from the filtrate using filter paper, and the first filtrate is passed after forming a filtration layer using powdered activated carbon to adsorb contaminants in the filtrate and absorb solvents and plants It may include a secondary filtration process to separate the chlorophyll component within.
상기 농축공정은 제3단계의 여과물의 성분을 농축하여 고순도의 성분을 획득하는 단계로 회전 감압 농축법은 감압농축기를 사용하여 건조·폐액 처리하는 단계로 추출액의 순수 추출물을 응집하고 층분리를 이용한 분획을 하는 단계일 수 있다.The concentration process is a step of concentrating the components of the filtrate in the third step to obtain high-purity components. It may be a step of fractionation.
이하, 본 발명의 이해를 돕기 위하여 실시예를 들어 상세하게 설명하기로 한다. 다만 하기의 실시예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다. 본 발명의 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, examples will be described in detail to aid understanding of the present invention. However, the following examples are merely illustrative of the contents of the present invention, but the scope of the present invention is not limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.
<실시예 1> 인디안구스베리 열매, 찔레나무 뿌리 및 쏘팔메토 열매의 혼합 추출물의 제조<Example 1> Preparation of Mixed Extracts of Indian Gooseberry Fruit, Brier Root and Saw Palmetto Fruit
본 실험에 사용한 재료는 서울 소재의 부영약업사에서 건조된 상태로 구입하여 사용하였다. 실험에 사용한 시약은 아세트산(acetic acid)와 수산화나트륨(sodium hydroxide), 염산(hydrogen chloride; HCl)은 덕산(Duksan, Korea), 염화나트륨(sodium chloride; NaCl)은 대정(Daejung, Korea) 제품을 구입 사용하였고, Tris-HCl는 Difco™ (Becton, Dickinson and Company, USA)에서 구입 및 사용하였다. DPPH, L-아스코르브산(L-ascorbic acid; vitamin C), 타닌산(tannic acid), 나린긴(naringin), 아질산나트륨(sodium nitrite), 디에틸렌글리콜(diethylene glycol), 그리스 시약(griess reagent), MTT, tryptic soy broth(TSB), 효모추출물(yeast extract), 맥아 추출물(malt extract), 펩톤(peptone), 덱스트로스(dextrose), 트립톤(tryptone), bacto agar는 Sigma-Aldrich(USA)에서 구입 및 사용하였다. Materials used in this experiment were purchased and used in a dried state from Booyoung Pharmacy in Seoul. The reagents used in the experiment were acetic acid and sodium hydroxide, hydrogen chloride (HCl) was purchased from Duksan (Korea), and sodium chloride (NaCl) was purchased from Daejung (Korea). Tris-HCl was purchased and used from Difco™ (Becton, Dickinson and Company, USA). DPPH, L-ascorbic acid (vitamin C), tannic acid, naringin, sodium nitrite, diethylene glycol, grease reagent, MTT, tryptic soy broth (TSB), yeast extract, malt extract, peptone, dextrose, tryptone, and bacto agar were obtained from Sigma-Aldrich (USA). Purchased and used.
또한, 소태아혈청(Fetal bovine serum; FBS), antibiotic-antimycotic, ethylenediaminetetraacetic acid (EDTA)는 Gibco™(Thermo Fisher Scientific, USA)에서 구입하였고, 세포배양에 사용한 인간모유두세포(HFDPC)는 PromoCell (Germany)에서 구입하였으며, 세포배양 배지는 인간모유두세포배양 전용배지인 follicle dermal papilla cell growth medium (C-26501; PromoCell)을 사용하였다. 모발성장인자 1차 항체인 혈소판유래성장인자 B 서브유닛(PDGFB)와 HGF는 Santa Cruz Biotechnology(USA)에서, KGF, IGF1, VEGF, 표피성장인자(EGF)는 PeproTech (USA)에서, 2차 항체인 goat anti-rabbit IgG-horseradish peroxidase(HRP)는 Santa Cruz Biotechnology에서 구입 및 사용하였다.In addition, fetal bovine serum (FBS), antibiotic-antimycotic, and ethylenediaminetetraacetic acid (EDTA) were purchased from Gibco™ (Thermo Fisher Scientific, USA), and human dermal papilla cells (HFDPC) used for cell culture were purchased from PromoCell (Germany). ), and follicle dermal papilla cell growth medium (C-26501; PromoCell), a medium exclusively for human hair papilla cell culture, was used as the cell culture medium. Platelet-derived growth factor B subunit (PDGFB) and HGF, which are primary hair growth factor antibodies, are from Santa Cruz Biotechnology (USA), and KGF, IGF1, VEGF, and epidermal growth factor (EGF) are from PeproTech (USA), and secondary antibodies Phosphorus goat anti-rabbit IgG-horseradish peroxidase (HRP) was purchased and used from Santa Cruz Biotechnology.
하기 표 1과 같은 제공 받은 전초 및 건조 원료에 대한 2차 건조 후 수분함량을 13 % 이하로 조절하여 분쇄기(IKA A11 basic)을 사용하여 40 mesh 이하로 분쇄한 분말을 -20 ℃로 보관하여 실험에 사용하였다.After the secondary drying of the provided outpost and dried raw materials as shown in Table 1 below, the moisture content was adjusted to 13% or less, and the powder ground to 40 mesh or less using a grinder (IKA A11 basic) was stored at -20 ° C and tested. used in
본 실험의 주요 원료인 인디안구스베리 열매, 찔레나무 뿌리 및 쏘팔메토 열매의 건조 시료를 별도의 40 mesh 이하로 2차 분쇄한 시료를 이용하여 추출 실험을 진행하였다.Extraction experiments were conducted using samples of secondary grinding of dried samples of Indian gooseberry fruit, bramble root, and saw palmetto fruit, which are the main raw materials of this experiment, with a separate 40 mesh or less.
상기 추출 실험시 진공저온감압 추출법을 사용하였으며, 분쇄시료 100 g에 10배의 증류수를 가한 다음 진공상태에서 끓는점을 낮추어 대류현상을 이용하여 60±2℃ 이하의 온도로 8시간씩 3회 반복하여 추출하였고 평균 수득률을 하기 표 2에 나타내었다.In the extraction experiment, a vacuum low-temperature decompression extraction method was used, and 10 times of distilled water was added to 100 g of the pulverized sample, and then the boiling point was lowered in a vacuum state, using a convection phenomenon. It was extracted and the average yield is shown in Table 2 below.
상기 샘플들에 대하여 최적의 유효성분을 찾기 위하여 각각의 추출물의 혼합 비율을 확인하여 최적의 중량비 조건을 찾기 위하여 혼합 추출물의 보습효과 실험을 진행하였다. 보습율은 건강한 모발의 기본적인 특성으로 두피 건강과 발모 개선에 가장 기초적 측정치로 적합한 혼합 비율을 확인할 수 있는 실험이다.In order to find the optimal active ingredient for the samples, the mixing ratio of each extract was checked and the moisturizing effect of the mixed extract was tested to find the optimal weight ratio condition. Moisturizing rate is a basic characteristic of healthy hair, and it is an experiment to confirm the appropriate mixing ratio as the most basic measure for improving scalp health and hair growth.
<실험예 1 내지 5> 통계처리<Experimental Examples 1 to 5> Statistical processing
모든 시료의 분석은 3번 반복하여 수행되었고, 실험결과는 사회과학을 위한 통계처리 패키지 프로그램(Statistical Package for the Social Sciences package program; SPSS ver.21, IBM, USA)을 사용하여 평균±표준편차(M±SD)로 표시하였고, 통계분석은 스튜던트의 T 검정(Student’s t-test)로 분석하였으며 p<0.05 값을 유의성 있는 것으로 해석하였다.The analysis of all samples was repeated three times, and the experimental results were average ± standard deviation ( M±SD), statistical analysis was analyzed by Student's t-test, and p<0.05 value was interpreted as significant.
<실험예 1> 혼합 추출물의 보습효과 확인 실험<Experimental Example 1> Experiment to confirm the moisturizing effect of the mixed extract
탈모방지 및 발모 개선용 기능성 화장료로서의 가능성을 확인하고 세 가지 추출물의 최적의 혼합률(중량비)를 확인하기 위해 원료 보습효과 실험을 진행하였다. 인디안구스베리열매 추출물, 찔레뿌리 추출물, 쏘팔메토 열매 추출물의 적정 혼합을 위한 중량비는 각각 1~5: 1~5: 1~5의 중량비를 기준으로 하였다.In order to confirm the possibility as a functional cosmetic for preventing hair loss and improving hair growth, and to confirm the optimal mixing ratio (weight ratio) of the three extracts, an experiment on the moisturizing effect of raw materials was conducted. The weight ratio for appropriate mixing of Indian gooseberry fruit extract, wild rose root extract, and saw palmetto fruit extract was based on a weight ratio of 1 to 5: 1 to 5: 1 to 5, respectively.
완전건조된 CaCl2를 흡습제로 사용하여 데시케이터 안에 담고 디쉬에 다음 각각의 비율별로 혼합된 추출물들을 각각 4 g씩 저울에 달아 상대습도 50 %, 35 ℃의 데시케이터에서 12시간 동안 각 시료의 무게를 3회 측정하여 표 3에 나타내었다.Using completely dried CaCl 2 as a desiccator, put it in a desiccator, put 4 g each of the extracts mixed by each ratio on a dish, and put each sample in a desiccator at 50% relative humidity and 35 ℃ for 12 hours. The weight of was measured three times and is shown in Table 3.
상기 표 3에서 복합추출물의 시간별 보습 효과는 중량비가 5: 1: 1인 경우 가장 우수하였으며, 중량비 5: 1: 1인 경우 보습력 확인을 위한 in vitro 테스트를 진행하고 그 결과를 표 4에 나타내었다.In Table 3, the moisturizing effect of the complex extract over time was the best when the weight ratio was 5: 1: 1, and in the case of the weight ratio 5: 1: 1, an in vitro test was conducted to confirm the moisturizing power, and the results are shown in Table 4 .
도 1은 보습력 테스트를 진행한 결과인 표 4에서 전체평균 및 비교 대조군의 데이터를 나타낸 그래프이다. 도 1을 참고하면, 필수 아미노산 계열의 성분함유와 압력에 의한 엑스트라의 유상계열 효과로 일반적인 수상계열보다 공기 중 기화 속도가 더딘 것을 확인할 수 있었다. 또한, 데시게이터 수분함유량 실험을 통해 원료성분강의 보습유지성분의 유효성을 확인할 수 있었다. 따라서, 액상 추출물에서 원료의 중량비로 총 중량 100 g 당 복합추출물들의 혼합비율은 인디안구스베리열매 추출물: 찔레뿌리 추출물: 쏘팔메토 열매 추출물이 5: 1: 1의 비율로 혼합(5: 1: 1 천연 복합추출물)될 때, 보습 효과가 가장 우수한 것으로 확인됨을 알 수 있다.Figure 1 is a graph showing the data of the overall average and comparative control group in Table 4, which is the result of the moisturizing power test. Referring to FIG. 1, it was confirmed that the vaporization rate in the air was slower than that of the general aqueous phase series due to the oil phase effect of the extra due to the essential amino acid series component content and pressure. In addition, through the desiccator moisture content test, the effectiveness of the moisturizing component of the raw material steel could be confirmed. Therefore, the mixing ratio of the complex extracts per 100 g of total weight in terms of the weight ratio of the raw materials in the liquid extract is Indian gooseberry fruit extract: Wildflower root extract: Saw Palmetto fruit extract mixed at a ratio of 5: 1: 1 (5: 1: 1 It can be seen that when it is a natural complex extract), the moisturizing effect is confirmed to be the best.
<실험예 2> 혼합 추출물의 항산화 효과 분석<Experimental Example 2> Antioxidant effect analysis of mixed extracts
2-1. 폴리페놀 화합물의 함량 측정 2-1. Measurement of content of polyphenol compounds
먼저, 준비한 시료 100 ㎕에 Folin-Dennis reagent(Fluka, Buchs, Switzerland)를 100 ㎕를 가하여 혼합한 후 3분간 실온에 반응시켰다. 3분 후 10 % 탄산나트륨 용액(sodium carbonate solution) 100 ㎕를 가하여 혼합하고 1시간 반응시킨 후 상층액을 취하여 마이크로플레이트 리더기(Microplate reader; Molecular Devices, Sunnyvale, CA, USA)를 이용하여 760 nm에서 흡광도를 측정하였다. 페놀 화합물의 함량은 메탄올(Methanol)에 녹인 10 ㎍/mL, 20 ㎍/mL, 30 ㎍/mL, 40 ㎍/mL, 50 ㎍/mL의 갈산(gallic acid)의 표준곡선을 이용하여 구하고 이를 표 5에 나타내었다.First, 100 μl of Folin-Dennis reagent (Fluka, Buchs, Switzerland) was added to 100 μl of the prepared sample, mixed, and reacted at room temperature for 3 minutes. After 3 minutes, 100 μl of 10% sodium carbonate solution was added and mixed, and after reacting for 1 hour, the supernatant was taken and the absorbance at 760 nm was measured using a microplate reader (Molecular Devices, Sunnyvale, CA, USA). was measured. The content of phenolic compounds was obtained using a standard curve of 10 μg/mL, 20 μg/mL, 30 μg/mL, 40 μg/mL, and 50 μg/mL gallic acid dissolved in methanol, and it was tabulated. 5.
2-2. 플라보노이드계 및 탄닌계의 페놀성 화합물들의 함량 측정2-2. Measurement of content of flavonoid and tannin phenolic compounds
플라보노이드(flavonoid)계 및 탄닌(tannin)계의 페놀성 화합물들의 함량은 Kim et al.(2012)의 방법으로 측정하였으며 메탄올(methanol)로 녹인 1 mg/mL 농도의 시료 100 ㎕에 디에틸렌글리콜(diethylene glycol)을 1 mL씩 가하여 혼합하였다. 혼합 후 1 N 수산화나트륨(sodium hydroxide)를 100 ㎕ 가하여 잘 혼합하고 37 ℃ 욕조(water bath)에서 1시간 동안 반응시켰다. 1시간 후, 마이크로플레이트 리더기를 이용하여 420 nm에서 흡광도를 측정하였다. 표준물질로 나린긴(naringin)을 사용하였으며, 10 ㎍/mL, 20 ㎍/mL, 30 ㎍/mL, 40 ㎍/mL, 50 ㎍/mL 농도의 표준검량곡선을 작성하여 플라보노이드계 및 탄닌계의 페놀성 화합물들의 함량을 환산하여 표 5에 나타내었다.The content of flavonoid-based and tannin-based phenolic compounds was measured by the method of Kim et al. (2012), and diethylene glycol ( diethylene glycol) was added and mixed by 1 mL. After mixing, 100 μl of 1 N sodium hydroxide was added, mixed well, and reacted in a 37° C. water bath for 1 hour. After 1 hour, absorbance was measured at 420 nm using a microplate reader. Naringin was used as a standard material, and standard calibration curves were prepared at concentrations of 10 μg/mL, 20 μg/mL, 30 μg/mL, 40 μg/mL, and 50 μg/mL to determine the concentration of flavonoids and tannins. The contents of phenolic compounds were converted and shown in Table 5.
표 5는 상기 각각의 추출물과 5: 1: 1 천연 복합추출물의 페놀 화합물들의 함량을 분석한 것이다. 표 5를 참고하면, 각각의 추출물의 함량 대비 5: 1: 1 천연 복합추출물의 총 페놀 화합물의 함량이 58.046±3.251 mg GAE/g, 총 플라보노이드계 및 탄닌계의 페놀성 화합물의 함량은 9.365±1.508 mg QE/g 으로 나타나 각각의 추출량 대비 현저히 높은 값을 나타냄을 확인할 수 있다. 따라서, 항산화 효과에 탁월한 폴리페놀의 함량이 높은 것을 알 수 있고, 이를 통해 5: 1: 1 천연 복합추출물의 우수한 항산화능을 확인할 수 있다.Table 5 is an analysis of the content of phenolic compounds in each of the extracts and the 5: 1: 1 natural composite extract. Referring to Table 5, the content of total phenolic compounds of the 5: 1: 1 natural composite extract was 58.046 ± 3.251 mg GAE / g, and the content of total flavonoid and tannin phenolic compounds was 9.365 ± It can be seen that it is 1.508 mg QE / g, indicating a significantly higher value compared to each extraction amount. Therefore, it can be seen that the content of polyphenol, which is excellent in antioxidant effect, is high, and through this, the excellent antioxidant ability of the 5: 1: 1 natural composite extract can be confirmed.
2-3. DPPH 라디칼 소거능 측정2-3. Measurement of DPPH radical scavenging activity
DPPH 라디칼 소거능은 Kim et al.(2012)의 방법으로 측정하였다. 시료는 메탄올에 녹여 1 mg/mL 농도로 준비하였으며, DPPH 시약은 빛을 차단한 상태에서 0.1 mM 농도가 되도록 메탄올에 녹여 준비하였다. 시료 100 ㎕ 와 DPPH 시약 0.5 mL을 넣어 최종농도가 0.2 mg/mL로 혼합된 시료를 20분 동안 빛을 차단한 조건에서 반응시킨 후 마이크로플레이트 리더기를 이용하여 517 nm에서 흡광도를 측정하였다. 음성대조군으로 시료 대신 메탄올을 사용하였고, 양성대조군으로는 시료 대신 1 mg/mL 농도의 아스코르브산(ascorbic acid)를 가하여 동일한 조건으로 실험을 수행하였다. DPPH 라디칼 소거능은 하기 식 1을 이용하여 DPPH 억제율을 산출하였다.DPPH radical scavenging ability was measured by the method of Kim et al. (2012). The sample was prepared by dissolving in methanol at a concentration of 1 mg/mL, and the DPPH reagent was prepared by dissolving in methanol to a concentration of 0.1 mM in a light-blocking state. After adding 100 μl of the sample and 0.5 mL of DPPH reagent to a final concentration of 0.2 mg/mL, the mixture was reacted under light-blocking conditions for 20 minutes, and the absorbance was measured at 517 nm using a microplate reader. As a negative control group, methanol was used instead of the sample, and as a positive control group, ascorbic acid at a concentration of 1 mg/mL was added instead of the sample, and the experiment was performed under the same conditions. DPPH radical scavenging ability was calculated by DPPH inhibition
[식 1][Equation 1]
DPPH 라디칼 스캐빈저 활동(DPPH radical scavenging activity, %)DPPH radical scavenger activity (DPPH radical scavenging activity, %)
=[1-(시료 처리군의 흡광도/시료 무처리군의 흡광도)]X100=[1-(absorbance of sample treated group/absorbance of untreated sample group)]X100
상기 식 1을 이용하여 DPPH 억제율을 산출하고 이를 도 2에 나타내었다. 도 2를 참고하여 DPPH 라디칼 소거능을 분석한 결과 5: 1: 1 천연 복합추출물은 98.24 %의 가장 높은 DPPH 라디칼 소거능을 보였다. 각각의 추출물의 DPPH 라디칼 소거능은 인디안구스베리열매 추출물이 76.87 %, 찔레뿌리 추출물이 35.85 %, 쏘팔메토 열매 추출물이 55.80 %로 나타남을 확인할 수 있다.The DPPH inhibition rate was calculated using
상기 DPPH 라디칼 소거능은 불안정한 유리기에 환원기능을 가진 양성자(proton)을 제공하여 안정화되도록 유도하는 기능으로 생체 내에서 발생하는 불안정하고 유해한 유리기를 안정화시키는 역할을 할 수 있다. 따라서, 미지의 특정물질이 생체의 생리작용 또는 산화작용에 의하여 발생하는 히드록시 라디칼(hydroxyl radical) 또는 초과산화물 라디칼(superoxide radical) 등을 제거하는 항산화 능력을 평가할 때 사용되는 지표로 높은 값일수록 항산화능이 우수한 것일 수 있다.The DPPH radical scavenging ability is a function of providing protons having a reducing function to unstable free radicals to induce them to be stabilized, and can play a role in stabilizing unstable and harmful free radicals generated in vivo. Therefore, it is an indicator used to evaluate the antioxidant ability of an unknown specific substance to remove hydroxyl radicals or superoxide radicals generated by physiological or oxidative actions of the living body. The higher the value, the more antioxidant. performance may be excellent.
2-4. 아질산염 소거능 측정2-4. Nitrite scavenging ability measurement
아질산염(nitrite) 소거능은 Gray&Dugan(1975)의 방법으로 측정하였다. 1 mM 아질산나트륨(sodium nitrite) 용액 50 ㎕에 1 mg/mL 농도의 시료 50 ㎕를 첨가하고, 여기에 0.1 N 염산(HCl)용액(pH 1.2)을 300 ㎕ 가하여 반응 용액의 최종부피를 0.4 mL로 하여 37 ℃에서 1시간 반응시켰다. 반응 후 2 % 아세트산용액 2 mL, 그리스 시약 0.2 mL를 가하여 최종 농도가 0.02 mg/mL로 잘 혼합한 다음 실온에서 15분간 반응시키고 마이크로플레이트 리더기를 이용하여 520 nm에서 흡광도를 측정하여 잔존하는 아질산염의 양을 산출하였다. 대조군으로 시료 대신 증류수를 사용하였고, 음성대조군으로 그리스 시약 대신 증류수를 사용하였고 양성대조군으로는 시료 대신 1 mg/mL 농도의 아스코브르산을 가하여 동일한 조건으로 실험을 수행하였다. 아질산염 소거능은 하기 식 2를 이용하여 억제율을 산출하고, 그 결과를 도 3에 나타내었다.Nitrite scavenging ability was measured by the method of Gray & Dugan (1975). 50 μl of 1 mg/mL sample was added to 50 μl of 1 mM sodium nitrite solution, and 300 μl of 0.1 N hydrochloric acid (HCl) solution (pH 1.2) was added thereto to make the final volume of the reaction solution 0.4 mL. and reacted at 37°C for 1 hour. After the reaction, add 2 mL of 2% acetic acid solution and 0.2 mL of grease reagent, mix well to a final concentration of 0.02 mg/mL, react at room temperature for 15 minutes, and measure the absorbance at 520 nm using a microplate reader to determine the amount of remaining nitrite. quantity was calculated. Distilled water was used instead of the sample as a control group, distilled water was used instead of the grease reagent as a negative control group, and ascorbic acid at a concentration of 1 mg/mL was added instead of the sample as a positive control group, and the experiment was performed under the same conditions. For the nitrite scavenging ability, the inhibition rate was calculated using Equation 2 below, and the results are shown in FIG. 3 .
[식 2][Equation 2]
아질산염 스캐빈저 활동(nitrite scavenging activity, %)Nitrite scavenging activity (%)
=[1-(시료 처리군의 흡광도/시료 무처리군의 흡광도)]X100=[1-(absorbance of sample treated group/absorbance of untreated sample group)]X100
도 3은 각각의 추출물과 천연 복합추출물의 아질산염 소거능을 분석한 그래프이다. 아질산염 소거능을 분석한 결과, 5: 1: 1 천연 복합추출물은 75.86 %의 가장 높은 아질산염 소거능을 보였으며, 각각의 추출물의 DPPH 라디칼 소거능은 인디안구스베리열매 추출물이 49.86 %, 찔레뿌리 추출물이 18.28 %, 쏘팔메토 열매 추출물이 22.76 %로 나타남을 확인할 수 있다.Figure 3 is a graph analyzing the nitrite scavenging ability of each extract and natural composite extract. As a result of analyzing the nitrite scavenging ability, the 5: 1: 1 natural composite extract showed the highest nitrite scavenging ability of 75.86%, and the DPPH radical scavenging ability of each extract was 49.86% for Indian gooseberry fruit extract, 18.28% for Brier root extract, and 18.28% for Indian gooseberry fruit extract. It can be seen that the saw palmetto fruit extract is 22.76%.
상기 아질산염은 산화제와 환원제로 작용하며 생체 내에서 산화질소 합성효소(nitric oxide synthase)라는 효소의 촉매작용을 통해 L-아르기닌(L-arginine)으로 변환되는 반응성이 강한 자유 라디칼로, 질산염(nitrate)은 아질산염으로 환원되고 아민(amine)류와 반응하여 나이트로소아민(nitrosamine)을 생성하는 것으로 알려져 있으며, 나이트로소아민은 체내에서 디아조알카인(diazoalkane; CnH2nN2)로 변화하여 핵산이나 단백질 또는 세포 내의 성분을 알킬화하여 암을 유발하고, 그 자신이 독성을 가지고 있는 것일 수 있다. 따라서, 아질산염을 소거하여 나이트로소아민의 생성을 억제할 수 있는 인체에 안전한 천연물은 기능성 화장품이나 식품보존에 및 천연 산패방지제로서 사용 가능할 것일 수 있다.The nitrite acts as an oxidizing agent and a reducing agent, and is a highly reactive free radical that is converted into L-arginine through the catalysis of an enzyme called nitric oxide synthase in vivo. It is known that silver is reduced to nitrite and reacts with amines to produce nitrosamine, which is converted into diazoalkane (C n H 2n N 2 ) in the body. It may cause cancer by alkylating nucleic acids, proteins, or intracellular components, and may itself be toxic. Therefore, a natural product that is safe for the human body capable of suppressing the production of nitrosamine by scavenging nitrite may be used for functional cosmetics or food preservation and as a natural anti-oxidation agent.
<실험예 3> 복합추출물의 모발 흑화 효과 분석<Experimental Example 3> Analysis of hair blackening effect of composite extract
3-1. 티로시나아제(tyrosinase) 활성 증가 효능 측정3-1. Measurement of tyrosinase activity increasing efficacy
멜라닌 생성에 관여하는 주요 효소인 티로시나아제의 활성 촉진 효능을 확인해보기 위해 머쉬룸 티로시나아제(mushroom tyrosinase, sigma, USA)를 사용하여 활성 증가 정도를 측정하였다. 96 웰 플레이트(well plate)에 80 mM 인산완충액(phosphate buffer, pH 6.8)에 8.3 mM의 농도로 녹여 조제한 L-3,4-다이하이드록시 페닐알라닌(L-3,4-dihydroxyphenyl alanine, L-DOPA) 용액 100 ㎕를 넣고 5: 1: 1 천연 복합추출물을 각각 최종 1 % 및 2 %가 되도록 50 ㎕씩 첨가하였다. 이후 80 mM 인산완충액에 250 U로 녹여 조제한 머쉬룸 티로시나아제를 각 웰 플레이트에 100 ㎕씩 첨가하였다. 30분간 37 ℃의 차광 배양기에서 반응시킨 후 멀티마이크로플레이트 리더기(multimicroplate reader)를 이용하여 475 mm에서 흡광도를 측정하여 하기 식 3과 같이 효소 활성 증가 효능을 계산하였으며, 그 결과를 도 4에 나타내었다.In order to confirm the activity promoting effect of tyrosinase, a major enzyme involved in melanin production, the degree of activity increase was measured using mushroom tyrosinase (sigma, USA). L-3,4-dihydroxyphenyl alanine (L-DOPA) prepared by dissolving at a concentration of 8.3 mM in 80 mM phosphate buffer (pH 6.8) in a 96-well plate ) 100 μl of the solution was added, and 50 μl of 5: 1: 1 natural composite extract was added to the final 1% and 2%, respectively. Thereafter, 100 μl of mushroom tyrosinase prepared by dissolving 250 U in 80 mM phosphate buffer was added to each well plate. After reacting in a shading incubator at 37 ° C. for 30 minutes, the absorbance was measured at 475 mm using a multimicroplate reader to calculate the enzyme activity increase efficiency as shown in Equation 3 below, and the results are shown in FIG. 4 .
[식 3][Equation 3]
티로시나아제 활성증가율(%) = 시료첨가군의 흡광도/ 대조군의 흡광도 X 100Tyrosinase activity increase rate (%) = absorbance of sample added group / absorbance of
도 4는 5: 1: 1 천연 복합추출물의 멜라닌 생성 촉진 효과가 티로시나아제(tyrosinase)활성 촉진에 의한 영향인지 알아보기 위하여 세포 티로시나아제 분석(cellular tyrosinase assay)를 수행한 결과를 나타낸 그래프이다. 천연 복합추출물을 0, 10, 20, 50 ㎍/mL의 농도로 처리한 세포를 수집하여 티로시나아제 활성을 측정한 결과, 농도 의존적으로 세포 내 티로시나아제의 활성이 증가하였으며 50 ㎍/mL 농도로 처리 시 95 %의 증가율을 보이는 것을 확인할 수 있었다. 따라서, 멜라닌 합성 과정의 주요한 효소인 티로시나아제의 활성이 증가하는 것을 통해, 고농도 처리시 천연 복합추출물의 모발흑화 효능이 우수한 것을 확인할 수 있다. Figure 4 is a graph showing the results of performing a cellular tyrosinase assay to determine whether the 5: 1: 1 natural composite extract has an effect of promoting melanin production by promoting tyrosinase activity. . Cells treated with natural complex extracts at concentrations of 0, 10, 20, and 50 μg/mL were collected and tyrosinase activity was measured. It was confirmed that an increase rate of 95% was observed when treated with the furnace. Therefore, through the increase in the activity of tyrosinase, a major enzyme in the melanin synthesis process, it can be confirmed that the natural complex extract has excellent hair blackening efficacy during high concentration treatment.
3-2. 멜라닌 생성 촉진 효능 측정3-2. Measurement of melanin production promoting efficacy
멜라닌 함량 측적은 Yasunobu 방법을 변형하여 사용하였다. 멜라닌 생성 촉진 효능을 확인해보기 위해 B16 melanoma 세포를 24 웰 플레이트에 각각 4 X 105의 세포 농도로 접종하여 37 ℃, 5 % CO2 배양기에서 24시간 동안 배양하였다. 배양 후, 배지를 제거하고 본 연구의 5: 1: 1 천연 복합추출물을 각각 0.1 % 및 1 %로 배지에 첨가하여 세포에 처리한 후 72시간 동안 배양하였다. 이 때, 샘플을 매일 1회 교체하였다. 멜라닌 생성률을 확인하기 위해 배지를 제거하고 세포를 PBS로 1회 세척하였다. 이후 1 N의 수산화나트륨(NaOH)를 각 웰에 500 ㎕씩 첨가하고 30분간 흔들어(shaking) 생성된 멜라닌을 녹여 멀티마이크로플레이트 리더기를 이용하여 405 nm에서 흡광도를 측정하여 하기 식 4와 같이 멜라닌 생성 증가 효능을 계산하였으며, 그 결과를 도 5에 나타내었다.Measurement of melanin content was used by modifying the Yasunobu method. In order to confirm the effect of promoting melanin production, B16 melanoma cells were inoculated into a 24-well plate at a cell concentration of 4 × 10 5 , respectively, and cultured for 24 hours at 37° C. in a 5% CO 2 incubator. After culturing, the medium was removed, and the 5: 1: 1 natural composite extract of this study was added to the medium at 0.1% and 1%, respectively, and the cells were treated and cultured for 72 hours. At this time, the sample was replaced once daily. To check the melanin production rate, the medium was removed and the cells were washed once with PBS. Thereafter, 500 μl of 1 N sodium hydroxide (NaOH) was added to each well, shaken for 30 minutes to dissolve the generated melanin, and the absorbance was measured at 405 nm using a multi-microplate reader to generate melanin as shown in Equation 4 below The increased efficacy was calculated, and the results are shown in FIG. 5 .
[식 4][Equation 4]
멜라닌 생성 증가율(%)= 시료첨가군의 흡광도/대조군의 흡광도 X 100Increase rate of melanin production (%) = absorbance of sample added group/absorbance of
도 5는 천연 복합추출물의 멜라닌 합성에 미치는 영향을 확인하기 위해 B16 melanoma 세포를 이용하여 멜라닌의 양을 측정한 그래프이다. 5: 1: 1 천연 복합추출물을 0, 10, 20, 50 ㎍/mL의 농도로 처리한 세포를 수집하여 멜라닌 양을 측정한 결과, 농도 의존적으로 멜라닌 합성이 증가되어 50 ㎍/mL 농도로 처리시 104 %의 증가율을 보임을 확인할 수 있다. 따라서, 멜라닌 생성 촉진 효능 시험에서 고농도의 천연 복합추출물의 멜라닌 생성이 증가하는 것을 통해 모발흑화 효능이 우수한 것을 확인할 수 있다.Figure 5 is a graph measuring the amount of melanin using B16 melanoma cells to determine the effect on melanin synthesis of natural composite extracts. Cells treated with 5: 1: 1 natural complex extract at concentrations of 0, 10, 20, and 50 μg/mL were collected and the amount of melanin was measured. It can be seen that an increase rate of 104% is shown. Therefore, in the melanin production promoting efficacy test, it can be confirmed that the hair blackening effect is excellent through the increase in melanin production of the high-concentration natural composite extract.
<실험예 4> 혼합 추출물의 인간 모유두세포(HFDPC)에 대한 시험관내(in vitro) 세포 독성 평가<Experimental Example 4> Evaluation of in vitro cytotoxicity of mixed extracts on human dermal papilla cells (HFDPC)
인간 모유두세포에 대한 세포독성도 조사(MTT assay)는 본 실험에서 세포의 배양과 계대배양 및 실험용 세포의 준비는 PromoCell에서 제공하는 실험법에 준하여 수행하였다. 인간 모유두세포에 미치는 생존율 측정은 Mosmann(1983)의 방법을 응용하여 실시하였다. 시험 추출물인 5: 1: 1 천연 복합추출물을 대조군과 함께 처리하였으며, 대조군으로 샘플을 용해하는데 사용된 인산완충생리식염수(phosphate buffered saline; PBS, Thermo Fisher Scientific)을 동량으로 처리하였다. 천연 복합추출물은 배양 배지 1 mL에 대하여 50 ㎕ 처리 후 최종 농도가 10, 100, 500 ㎍/mL가 되도록 처리하였다. 배양 완료 후, 100 ㎕의 MTT 용액을 각 웰에 첨가하고 3시간 동안 추가로 세포 배양기에서 배양하여 MTT가 환원되도록 하였다. 배양액을 완전히 제거한 후 마이크로플레이트 리더기를 이용하여 550 nm에서 흡광도를 측정하였다.In the cytotoxicity test (MTT assay) on human dermal papilla cells, cell culture, subculture, and preparation of cells for experiments in this experiment were performed according to the test method provided by PromoCell. The survival rate on human dermal papilla cells was measured by applying the method of Mosmann (1983). The test extract, 5: 1: 1 natural composite extract, was treated with a control group, and the same amount of phosphate buffered saline (PBS, Thermo Fisher Scientific) used to dissolve the sample was treated as a control group. The natural complex extract was treated to a final concentration of 10, 100, or 500 μg/mL after 50 μl treatment with respect to 1 mL of the culture medium. After completion of the incubation, 100 μl of MTT solution was added to each well and cultured in a cell incubator for an additional 3 hours to reduce MTT. After completely removing the culture medium, absorbance was measured at 550 nm using a microplate reader.
도 6은 인간 모유두세포에 대하여 5: 1: 1 천연 복합추출물을 농도별로 처리하여 MTT assay로 세포 독성을 확인하여 세포 생육도를 나타낸 그래프이다. 도 6을 참고하면, PBS를 처리한 대조군과 대비하여, 10 ㎍/mL 처리는 94.4±3 %, 100 ㎍/mL 처리는 95.5±5 %, 500 ㎍/mL 처리는 113.1±6 %의 세포 생육도를 나타냄을 알 수 있다. 따라서 5: 1: 1 천연 복합추출물은 10, 100, 500 ㎍/mL의 농도 범위내에서는 인간 모유두세포에 대한 유의적인 세포 독성은 관찰되지 않았으며, 500 ㎍/mL 처리시 PBS를 처리한 대조군 대비 113.1 %의 세포 생육도를 보여 육모제 소재로서 개발 가능성이 높다는 것을 알 수 있다.Figure 6 is a graph showing the degree of cell viability by treating 5: 1: 1 natural composite extract with respect to human dermal papilla cells by concentration and confirming cytotoxicity by MTT assay. Referring to Figure 6, compared to the control group treated with PBS, cell growth of 94.4 ± 3% in the 10 μg / mL treatment, 95.5 ± 5% in the 100 μg / mL treatment, and 113.1 ± 6% in the 500 μg / mL treatment It can be seen that the figure represents Therefore, the 5: 1: 1 natural composite extract did not show significant cytotoxicity to human dermal papilla cells within the concentration range of 10, 100, and 500 μg/mL, and when treated with 500 μg/mL, compared to the control group treated with PBS. It shows a cell growth rate of 113.1%, indicating that it has a high potential for development as a hair restorer material.
<실험예 5> 웨스턴블랏(Western blot)을 통한 혼합 추출물의 모발성장인자 단백질 발현 측정<Experimental Example 5> Measurement of hair growth factor protein expression of mixed extracts through Western blot
인간 모유두세포를 계대배양한 후 5: 1: 1 천연 복합추출물을 100 ㎍/mL의 농도로 처리한 후, 48시간 뒤에 세포에서 발현되는 6가지의 성장인자(PDGFB, KGF, IGF1, VEGF, HGF, EGF) 단백질들의 발현을 폴리아크릴아마이드 겔 전기 영동법(SDS-PAGE)로 분리하고 웨스턴블랏을 이용하여 측정하였다. 인간 모유두세포를 48시간 배양한 후, 인산완충생리식염수로 2회 세척하고 2 % NET buffer(150 mM NaCl; 5 mM EDTA, pH 8; 50 mM Tris-HCl, pH 7.4)를 이용하여 세포를 용해하고 음파처리(sonication)을 통해 세포추출물을 제조하였다. 세포추출물의 단백질 정량은 소혈청알부민(bovine serum albumin)을 표준물질로 간략하게 퀵 스타트 브래드퍼드 단백질 정량법(Quick StartTM Bradford Protein Assay, Bio-Rad Laboratories, USA)를 이용하여 정량하였다. 단백질을 정량한 시료는 각 웰당 20 ㎍ 의 단백질량을 로딩하여 10 % SDS-PAGE에서 150 V로 1시간 전기영동하고 일렉트로블로팅 시스템(electro-blotter, Gel company, USA)를 사용하여 탈지유 용액(skim milk solution)에 필터(filter)를 담그고 12시간 배양하였다. 이후 인산완충생리식염수 세척액으로 10분간 3회 세척하고 2,500배 희석된 1차 항체(PDGFB, KGF, IGF1, VEGF, HGF, EGF)를 이용하여 1.5시간 동안 반응시켰으며, 세척액으로 3회 세척한 후 2,500배 희석된 2차 항체인 goat anti-rabbit IgG-HRP를 1시간 동안 반응시키고 세척액으로 3회 세척한 후 ECL kit(RPN 2108; AmershamTM, GE Healthcare Life Sciences)를 이용하여 필름에 감광시키는 방법을 이용하여 단백질의 발현을 조사하였다. 밴드의 밀도(Band density)는 전기영동 이미지 분석 시스템(gel imaging system, Gel DocTM EZ system 1708270; Bio-Rad Laboratories)으로 확인하였다.After subculture of human dermal papilla cells, 5: 1: 1 natural composite extract was treated at a concentration of 100 μg/mL, and 48 hours later, six growth factors (PDGFB, KGF, IGF1, VEGF, HGF) expressed in cells , EGF) proteins were separated by polyacrylamide gel electrophoresis (SDS-PAGE) and measured by Western blotting. After culturing human dermal papilla cells for 48 hours, wash them twice with phosphate buffered saline and lyse the cells using 2% NET buffer (150 mM NaCl; 5 mM EDTA, pH 8; 50 mM Tris-HCl, pH 7.4). And a cell extract was prepared by sonication. Protein quantification of the cell extract was quantified using bovine serum albumin as a standard material simply by Quick Start TM Bradford Protein Assay (Bio-Rad Laboratories, USA). Protein quantified samples were loaded with 20 μg of protein per well, electrophoresed on 10% SDS-PAGE at 150 V for 1 hour, and skim milk solution ( A filter was immersed in skim milk solution and incubated for 12 hours. Afterwards, the cells were washed 3 times for 10 minutes with phosphate-buffered saline washing solution and reacted for 1.5 hours using 2,500-fold diluted primary antibodies (PDGFB, KGF, IGF1, VEGF, HGF, EGF), and washed 3 times with washing solution. A method of reacting with goat anti-rabbit IgG-HRP, a secondary antibody diluted 2,500 times for 1 hour, washing three times with a washing solution, and then photosensitizing the film using an ECL kit (RPN 2108; Amersham TM , GE Healthcare Life Sciences) was used to investigate protein expression. Band density was confirmed by an electrophoretic image analysis system (gel imaging system, Gel Doc TM EZ system 1708270; Bio-Rad Laboratories).
도 7은 인간 모유두세포에 5: 1: 1 천연 복합추출물을 100 ㎍/mL의 농도로 48시간동안 처리한 후, 모발성장인자 단백질인 상기 6가지의 성장인자들의 발현 정도에 미치는 영향을 웨스턴블랏을 통해 측정한 그래프이다. 상기 성장인자들의 모발성장에 미치는 영향에 관해서 EGF, IGF, FGF, VEGF 등의 성장인자들은 여러 실험을 통하여 모낭의 특정 장소에 작용하여 모발성장에 관여한다고 이미 밝혀진 바 있다(Tsuboi, 1997).Figure 7 is a Western blot showing the effect on the expression level of the six growth factors, which are hair growth factor proteins, after treating human dermal papilla cells with a 5: 1: 1 natural composite extract at a concentration of 100 μg/mL for 48 hours. It is a graph measured through Regarding the effect of the above growth factors on hair growth, it has been previously revealed that growth factors such as EGF, IGF, FGF, and VEGF are involved in hair growth by acting on a specific site of the hair follicle through various experiments (Tsuboi, 1997).
도 7을 참고하면, 5: 1: 1 천연 복합추출물의 처리시 PBS를 사용한 대조군과 대비하여 IGF1과 PDGFB에서 각각 135±8 %, 126±11 %로 발현촉진효과가 나타났고 나머지 성장인자들에서는 HGF가 106±10 %, KGF가 100±6 %, VEGF가 99±11 %, EGF가 97±10 %의 단백질 발현 정도를 확인할 수 있으며, 상기 천연 복합추출물이 모발성장에 도움이 되는 것을 알 수 있다.Referring to Figure 7, when treated with a 5: 1: 1 natural composite extract, compared to the control group using PBS, IGF1 and PDGFB showed expression promoting effects of 135 ± 8% and 126 ± 11%, respectively, and the rest of the growth factors HGF was 106±10%, KGF was 100±6%, VEGF was 99±11%, and EGF was 97±10%. there is.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.As above, specific parts of the present invention have been described in detail, and for those skilled in the art, it is clear that these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereby. something to do. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (10)
2) 상기 동결한 건조 분말 원료를 55 내지 65 ℃에서 진공저온감압 추출하는 단계(제2단계);
3) 여과하여 잔유물을 분리하고 여과물을 수득하는 단계(제3단계);
4) 상기 여과물을 회전 감압 농축하는 단계(제4단계); 및
5) 상기 감압 농축처리된 추출물을 동결 건조하여 천연 혼합 원료를 얻는 단계(제5단계)를 포함하는 인디안구스베리 열매, 찔레나무 뿌리 및 쏘팔메토 열매의 추출물이 5:1:1의 중량비로 포함되는 조성물을 유효성분으로 함유한 조성물의 제조방법.1) drying, pulverizing and freezing the dry powder raw material (first step);
2) vacuum low-temperature and reduced pressure extraction of the frozen dry powder raw material at 55 to 65 ° C. (second step);
3) filtering to separate the residue and obtain a filtrate (third step);
4) concentrating the filtrate under reduced pressure by rotation (fourth step); and
5) Extracts of Indian gooseberry fruit, bramble root and saw palmetto fruit, including the step of obtaining a natural mixed raw material by freeze-drying the concentrated extract under reduced pressure (step 5), included in a weight ratio of 5: 1: 1 A method for producing a composition containing the composition as an active ingredient.
The method for preparing a composition according to claim 7, wherein the filtration comprises a step of using filter paper (first) and powdered activated carbon (second).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220057188A KR102481945B1 (en) | 2022-05-10 | 2022-05-10 | Cosmetic composition for scalp and hair containing natural complex extract as an active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220057188A KR102481945B1 (en) | 2022-05-10 | 2022-05-10 | Cosmetic composition for scalp and hair containing natural complex extract as an active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102481945B1 true KR102481945B1 (en) | 2022-12-29 |
Family
ID=84539515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220057188A KR102481945B1 (en) | 2022-05-10 | 2022-05-10 | Cosmetic composition for scalp and hair containing natural complex extract as an active ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102481945B1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130003655A (en) * | 2011-06-30 | 2013-01-09 | 주식회사 이롬 | Composition for prevention of hair loss and promotion of hair growth which contains rosa multiflora extract as an active ingredient |
KR20130084441A (en) * | 2012-01-17 | 2013-07-25 | 정태용 | Making method of fucoidan from the root extract of tangleweed |
KR101780692B1 (en) | 2015-06-24 | 2017-09-25 | 주식회사 티젠 농업회사법인 | Composition comprising natural mixture extract for preventing lose of hair or promoting growth of hair |
KR20180013422A (en) * | 2016-07-29 | 2018-02-07 | 주식회사 티젠 농업회사법인 | Composition comprising Amla extract for preventing lose of hair or promoting of hair |
KR101953257B1 (en) * | 2018-04-30 | 2019-02-28 | 가라사대주식회사 | Composition for preventing hair loss and growing hair comprising tulip, saw palmetto, nettle extracts |
-
2022
- 2022-05-10 KR KR1020220057188A patent/KR102481945B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130003655A (en) * | 2011-06-30 | 2013-01-09 | 주식회사 이롬 | Composition for prevention of hair loss and promotion of hair growth which contains rosa multiflora extract as an active ingredient |
KR20130084441A (en) * | 2012-01-17 | 2013-07-25 | 정태용 | Making method of fucoidan from the root extract of tangleweed |
KR101780692B1 (en) | 2015-06-24 | 2017-09-25 | 주식회사 티젠 농업회사법인 | Composition comprising natural mixture extract for preventing lose of hair or promoting growth of hair |
KR20180013422A (en) * | 2016-07-29 | 2018-02-07 | 주식회사 티젠 농업회사법인 | Composition comprising Amla extract for preventing lose of hair or promoting of hair |
KR101953257B1 (en) * | 2018-04-30 | 2019-02-28 | 가라사대주식회사 | Composition for preventing hair loss and growing hair comprising tulip, saw palmetto, nettle extracts |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101704874B1 (en) | Cosmetic Compositions with Whitening and Anti-oxidative Effect Comprising of Phragmitis Rhizoma, Salicomia herbacea L. and Prunus mume | |
EP3380201B1 (en) | Anti-pollution complex comprising oily and aqueous calendula extracts and an aqueous extract of lilium candidum bulb and uses thereof | |
KR20140012964A (en) | Extract of aerial parts of maca rich in polyphenols and composition comprising same | |
TWI466686B (en) | Whitening agents, anti-aging agents and antioxidants, and whitening endermic agents, anti-aging and anti-skin external oxidation method for producing a skin external preparation of | |
KR20130058107A (en) | Isolation and preparation of small peptides from soybean and its cosmetic composition | |
CN105267268B (en) | Method for preparing folium Ginseng extract and cosmetic composition containing the same as effective component | |
KR20140126892A (en) | External composition for skin containing Ginsenoside Rg3 | |
KR101199209B1 (en) | Cosmetic composition containing fermented extracts with salt of natural materials | |
KR20110068949A (en) | A plum tree extract, a method for preparing the plum tree extract and use thereof | |
KR20140021315A (en) | Cosmetic compositon for skin-irritation alleviation with inula britannica var. chinensis, cynanchi radix and lysimachia foenum-graecum hance | |
KR102481945B1 (en) | Cosmetic composition for scalp and hair containing natural complex extract as an active ingredient | |
KR102067639B1 (en) | The Cosmetic Composition For The Improvement of Anti-Oxidant and Whitening Effect Including The Extract Of Rhus javanica L. As An Active Ingredient | |
KR102463745B1 (en) | Cosmetic composition with brightening and antioxidant function | |
KR20210091430A (en) | Cosmetic composition containing natural complex extracts as active ingredient | |
KR20070023845A (en) | Cosmetic composition comprising extracts of ginkgo biloba l. and process of manufacturing their products | |
KR20210024357A (en) | Antioxidant and moisturizing cosmetic composition containing mixed extracts including Prunus yedoensis flower, Peach tree flower and Chrysanthemum flower extract | |
KR101456059B1 (en) | The cosmetic composition effective in whitening and anti-aging mainly comprised of roasted licorice extract | |
KR102612017B1 (en) | Composition for skin improvement comprising multiple extract | |
KR20140126891A (en) | External composition for skin containing Ginsenoside Rf | |
KR101822043B1 (en) | Cosmetic Compositions Containing complex Extracts of Nymphaea Caerulea and Cetraria islandica | |
JP2011001328A (en) | INHIBITOR ON INCREASE IN BASIC FIBROBLAST CELL PROLIFERATION FACTOR mRNA EXPRESSION | |
KR101909533B1 (en) | Composition of skin external application containing ginsenoside F1 | |
KR102615332B1 (en) | Cosmetic composition comprising Feverfew extract | |
KR20140131027A (en) | Skin external composition containing ginsenoside Rh4 | |
KR20240018829A (en) | Composition for preventing and ameliorating hair removal containing black beans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |